{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:17:36Z","timestamp":1793521056870,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jacc.2025.08.047","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:43:48Z","timestamp":1759211028000},"page":"1381-1404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":206,"title":["Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement"],"prefix":"10.1016","volume":"87","author":[{"given":"George A.","family":"Mensah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanth D.","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine K.","family":"Welty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.08.047_bib1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.047_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/cvr\/cvaa211","article-title":"Inflammation and cardiovascular diseases: lessons from seminal clinical trials","volume":"117","author":"Liberale","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.08.047_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib4","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure: JACC State-of-the-Art Review","volume":"75","author":"Murphy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/CIRCRESAHA.116.303577","article-title":"The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis","volume":"119","author":"Prabhu","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.08.047_bib6","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa1208536","article-title":"A randomized trial of colchicine for acute pericarditis","volume":"369","author":"Imazio","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib8","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.047_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(08)60134-8","article-title":"Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial","volume":"371","author":"Torre-Amione","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.047_bib10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.047_bib11","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib13","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib14","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.047_bib16","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib17","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib18","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib19","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib20","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJM198910193211601","article-title":"A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy","volume":"321","author":"Parrillo","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib21","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.047_bib22","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/eurheartj\/ehp249","article-title":"Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study","volume":"30","author":"Frustaci","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.047_bib23","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A test in context: high-sensitivity C-reactive protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib24","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/01.CIR.0000125690.80303.A8","article-title":"Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores","volume":"109","author":"Ridker","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.047_bib25","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","article-title":"Clinician\u2019s guide to reducing inflammation to reduce atherothrombotic risk","volume":"72","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.047_bib27","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib28","first-page":"ehaf209","article-title":"Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study","author":"Kraaijenhof","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.047_bib29","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1093\/eurheartj\/ehae565","article-title":"Universal screening for hsCRP in patients with atherosclerotic disease: a major therapeutic opportunity","volume":"45","author":"Liuzzo","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.047_bib30","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jacbts.2023.10.007","article-title":"Advances in clinical imaging of vascular inflammation: a state-of-the-art review","volume":"9","author":"West","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacc.2025.08.047_bib31","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ehjci\/jeae314","article-title":"Estimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?","volume":"26","author":"Annink","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.08.047_bib32","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1093\/eurheartj\/ehad484","article-title":"Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers","volume":"44","author":"Antoniades","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.047_bib33","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(24)00596-8","article-title":"Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study","volume":"403","author":"Chan","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.047_bib34","series-title":"Effect of colchicine on progression of known coronary atherosclerosis in patients with stable coronary artery disease compared to placebo - Ekstrom Trial","author":"Budoff","year":"2025"},{"key":"10.1016\/j.jacc.2025.08.047_bib35","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.047_bib37","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/eurheartj\/ehad867","article-title":"C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project","volume":"45","author":"Arnold","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.047_bib38","first-page":"ehaf658","article-title":"C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the \u2018SMuRF-less but inflamed\u2019","author":"Ridker","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.047_bib39","article-title":"Occurrence of coronary events in the absence of traditional risk factors: understanding residual risk","author":"Arnold","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.08.047_bib40","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/eurheartj\/ehad055","article-title":"Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein","volume":"44","author":"Thomas","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.047_bib41","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis","volume":"78","author":"Zhang","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib42","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.jacc.2009.10.006","article-title":"Clinical implications of JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin) in a U.S. population insights from the ARIC (atherosclerosis risk in communities) study","volume":"54","author":"Yang","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib43","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.mayocp.2022.10.013","article-title":"Association of initial and longitudinal changes in C-reactive protein with the risk of cardiovascular disease, cancer, and mortality","volume":"98","author":"Suthahar","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2025.08.047_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2024-004148","article-title":"Cardiovascular disease risk factors and their associations with inflammation among US adolescents: NHANES, 2015 to March 2020","volume":"12","author":"Casagrande","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jacc.2025.08.047_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MOL.0000000000000922","article-title":"C-reactive protein, pharmacological treatments and diet: how to target your inflammatory burden","volume":"35","author":"Bay","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2025.08.047_bib46","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/eurheartj\/ehq022","article-title":"Clinical implications of inflammation for cardiovascular primary prevention","volume":"31","author":"Libby","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.047_bib47","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib48","article-title":"Statins for the \u201cSMuRFLess but inflamed\u201d: silent vascular inflammation and the challenge of translational science","volume":"10","author":"Ridker","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacc.2025.08.047_bib49","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib50","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacc.2025.08.047_bib51","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.047_bib52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.047_bib53","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1093\/eurheartj\/ehae557","article-title":"Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease","volume":"45","author":"Mazhar","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.047_bib54","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib55","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib56","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.047_bib57","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(24)00968-1","article-title":"Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial","volume":"404","author":"Kelly","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.047_bib58","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJMe2416329","article-title":"Timing the taming of vascular inflammation","volume":"392","author":"Loscalzo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib59","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41569-025-01124-3","article-title":"Colchicine in acute coronary syndromes: the present and the possible future","volume":"22","author":"Imazio","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/FJC.0000000000001672","article-title":"Colchicine in coronary artery disease: where do we stand?","volume":"85","author":"Bonaventura","year":"2025","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2025.08.047_bib61","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s44161-024-00600-2","article-title":"Implications and limitations of the CLEAR-SYNERGY trial for the use of low-dose colchicine in cardiovascular disease","volume":"4","author":"Misra","year":"2025","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.08.047_bib62","first-page":"843","article-title":"Efficacy and safety of colchicine and spironolactone after myocardial infarction: the CLEAR-SYNERGY trial in perspective","volume":"13","author":"Tardif","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jacc.2025.08.047_bib63","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.jacc.2025.03.536","article-title":"Colchicine for cardiovascular disease: navigating the gap between evidence, guidelines, and clinical practice","volume":"85","author":"Ridker","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib64","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/eurheartj\/ehaf174","article-title":"Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis","volume":"46","author":"Samuel","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.047_bib65","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/eurheartj\/ehae208","article-title":"Low-dose colchicine for atherosclerosis: long-term safety","volume":"45","author":"Nidorf","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.047_bib66","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/ehjqcco\/qcaa045","article-title":"Cost-effectiveness of low-dose colchicine after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT)","volume":"7","author":"Samuel","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jacc.2025.08.047_bib67","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.047_bib68","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","article-title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","volume":"30","author":"Chertow","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib69","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.jacc.2020.09.535","article-title":"Dietary inflammatory potential and risk of cardiovascular disease among men and women in the U.S","volume":"76","author":"Li","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib70","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2020.12.017","article-title":"Fish consumption and cardiovascular health: a systematic review","volume":"134","author":"Krittanawong","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib71","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/ATVBAHA.122.318125","article-title":"Fish and omega-3 fatty acids: sex and racial differences in cardiovascular outcomes and cognitive function","volume":"44","author":"Welty","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.08.047_bib72","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-158-7-201304020-00003","article-title":"Plasma phospholipid long-chain \u03c9-3 fatty acids and total and cause-specific mortality in older adults: a cohort study","volume":"158","author":"Mozaffarian","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib73","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000506","article-title":"Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the multi-ethnic study of atherosclerosis","volume":"2","author":"de Oliveira Otto","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.08.047_bib74","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jamainternmed.2016.2925","article-title":"\u03c9-3 polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies","volume":"176","author":"Del Gobbo","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib75","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1038\/s41467-021-22370-2","article-title":"Fatty Acids and Outcomes Research Consortium (FORCE). Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies","volume":"12","author":"Harris","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2025.08.047_bib76","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.121.055654","article-title":"Effect of long-term marine \u0277-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis","volume":"144","author":"Gencer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.047_bib77","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.mayocp.2020.08.034","article-title":"Effect of omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials","volume":"96","author":"Bernasconi","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2025.08.047_bib78","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2025.08.047_bib79","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1126\/science.1230720","article-title":"Anti-inflammatory therapy in chronic disease: challenges and opportunities","volume":"339","author":"Tabas","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jacc.2025.08.047_bib80","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jacc.2004.12.077","article-title":"The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review","volume":"45","author":"Kasapis","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib81","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41569-023-00984-x","article-title":"Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease","volume":"21","author":"Fredman","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib82","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1152\/japplphysiol.01004.2002","article-title":"Physical exercise increases urinary excretion of lipoxin A4 and related compounds","volume":"94","author":"Gangemi","year":"2003","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.jacc.2025.08.047_bib83","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nm.3911","article-title":"Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections","volume":"21","author":"Dalli","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib84","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jacc.2022.07.004","article-title":"Exercise for primary and secondary prevention of cardiovascular disease: JACC Focus Seminar 1\/4","volume":"80","author":"Tucker","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib85","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","article-title":"Reappraising the role of inflammation in heart failure","volume":"17","author":"Adamo","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib86","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1161\/CIRCRESAHA.124.323659","article-title":"Myocardial inflammation in heart failure with reduced and preserved ejection fraction","volume":"134","author":"Alcaide","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.08.047_bib87","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1161\/CIRCRESAHA.123.323656","article-title":"The emerging field of cardioimmunology: past, present and foreseeable future","volume":"134","author":"Mann","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.08.047_bib88","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","volume":"454","author":"Medzhitov","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2025.08.047_bib89","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","article-title":"C-reactive protein in heart failure: prognostic value and the effect of valsartan","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.047_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1064967","article-title":"C-reactive protein and statins in heart failure with reduced and preserved ejection fraction","volume":"9","author":"Park","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib91","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/ehf2.12724","article-title":"Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas","volume":"7","author":"Bajaj","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.047_bib92","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41569-021-00520-9","article-title":"Electroimmunology and cardiac arrhythmia","volume":"18","author":"Grune","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib93","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/cvr\/cvaf017","article-title":"Immune cells and arrhythmias","volume":"121","author":"Keefe","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.08.047_bib94","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCRESAHA.124.324871","article-title":"Interface between cardioimmunology, myocardial health, and disease: a compendium","volume":"134","author":"Campos Ramos","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.08.047_bib95","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.047_bib96","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/ehf2.12681","article-title":"Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature","volume":"7","author":"Bajaj","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.047_bib97","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cardfail.2023.10.024","article-title":"HERMES: effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation (abstr)","volume":"30","author":"Petrie","year":"2024","journal-title":"J Card Fail"},{"issue":"16","key":"10.1016\/j.jacc.2025.08.047_bib98","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","article-title":"Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST)","volume":"103","author":"Deswal","year":"2001","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacc.2025.08.047_bib99","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","article-title":"C-reactive protein in heart failure: prognostic value and the effect of valsartan","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.047_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131818","article-title":"High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: findings from TOPCAT","volume":"402","author":"Ferreira","year":"2024","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.jacc.2025.08.047_bib101","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jchf.2023.06.031","article-title":"Interleukin-6 in patients with heart failure and preserved ejection fraction","volume":"11","author":"Alogna","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.jacc.2025.08.047_bib102","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1002\/ehf2.14959","article-title":"IL-6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction","volume":"11","author":"Berger","year":"2024","journal-title":"ESC Heart Failure"},{"issue":"15","key":"10.1016\/j.jacc.2025.08.047_bib103","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacc.2025.08.047_bib104","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jacc.2025.08.047_bib106","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.acvd.2024.12.005","article-title":"Abatacept dose-finding phase II trial for immune checkpoint inhibitors myocarditis (ACHLYS) trial design","volume":"118","author":"Salem","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2025.08.047_bib107","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/jama.2024.12935","article-title":"Diagnosis, risk stratification, and treatment of pericarditis: a review","volume":"332","author":"Cremer","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.08.047_bib108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jacc.2023.05.013","article-title":"Recurrent pericarditis: a promising future for IL-1 blockers in autoinflammatory phenotypes","volume":"82","author":"Klein","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib109","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.2014.11026","article-title":"Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial","volume":"312","author":"Imazio","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.08.047_bib110","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.08.047_bib111","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jacc.2023.04.046","article-title":"Treatment of idiopathic recurrent pericarditis with goflikicept: phase II\/III study results","volume":"82","author":"Myachikova","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib112","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jcmg.2024.04.010","article-title":"Pericardial diseases: international position statement on new concepts and advances in multimodality cardiac imaging","volume":"17","author":"Klein","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.08.047_bib113","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib114","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trsl.2021.11.004","article-title":"Novel associations between inflammation-related proteins and adiposity: a targeted proteomics approach across four population-based studies","volume":"242","author":"Ponce-de-Leon","year":"2022","journal-title":"Transl Res"},{"key":"10.1016\/j.jacc.2025.08.047_bib115","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014959","article-title":"Coronary inflammation and plaque vulnerability: a coronary computed tomography and optical coherence tomography study","volume":"16","author":"Yuki","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.08.047_bib116","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib117","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2023.03.401","article-title":"Clonal hematopoiesis of indeterminate potential predicts adverse outcomes in patients with atherosclerotic cardiovascular disease","volume":"81","author":"Gumuser","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib119","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/s41591-024-03188-z","article-title":"Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials","volume":"30","author":"Marston","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.08.047_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOH.0000000000000688","article-title":"Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease","volume":"29","author":"Cobo","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jacc.2025.08.047_bib121","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.08.047_bib122","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002471R","article-title":"Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B4","volume":"35","author":"Welty","year":"2021","journal-title":"FASEB J"},{"issue":"9","key":"10.1016\/j.jacc.2025.08.047_bib123","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1172\/JCI97947","article-title":"Pro-resolving lipid mediators in vascular disease","volume":"128","author":"Conte","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2025.08.047_bib124","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jss.2019.01.038","article-title":"Fish oil increases specialized pro-resolving lipid mediators in PAD (The OMEGA-PAD II Trial)","volume":"238","author":"Ramirez","year":"2019","journal-title":"J Surg Res"},{"key":"10.1016\/j.jacc.2025.08.047_bib125","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/ATVBAHA.124.319980","article-title":"Novel therapeutics and upcoming clinical trials targeting inflammation in cardiovascular diseases","volume":"44","author":"Potere","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.08.047_bib126","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ehjcvp\/pvad074","article-title":"Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease","volume":"10","author":"Zheng","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2025.08.047_bib127","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/0109298673311105240902053715","article-title":"Lipids and inflammation: novel molecular targets and therapeutic implications","volume":"32","author":"Triglia","year":"2025","journal-title":"Curr Med Chem"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725075552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725075552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:49:57Z","timestamp":1774363797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725075552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":127,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0735109725075552"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.047","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}